Assessment of the prognostic ability of the platelet-to-lymphocyte ratio in patients with myocardial revascularization after coronavirus infection

Despite the advances in interventional cardiology, the problem of coronary restenosis remains relevant. An important factor in the pathogenesis of restenosis is the inflammatory process in the vascular intima. The aim of the study is to evaluate the relationship between the platelet-to-lymphocyte ratio (PLR), clinical and laboratory parameters in patients with repeat myocardial revascularization, and to analyze its prognostic value for clinical outcomes.

Material and methods. A crosssectional study included 931 patients who underwent repeat myocardial revascularization between May 2020 and May 2023. In-stent restenosis was detected in 420 patients in the main group, of which 162 patients previously had COVID-19. The control group included 511 patients without in-stent restenosis (107 patients previously had COVID-19). All registered events were verified by the hospital's electronic records in the Integrated Medical Information System.

Results. The regression analysis showed a statistically significant association of PLR with neutrophil and creatinine levels in both study groups, as well as with AST in the main group. PLR is not a significant predictor of myocardial infarction with coronary artery restenosis (OR = 1.0). Also, no relationship was found between the survival of patients with repeat revascularization and PLR.

Conclusion. An association of PLR with some laboratory parameters was determined, but its prognostic value for myocardial infarction with coronary artery restenosis was not found.

1. Kim M.S., Dean L.S. In-stent restenosis. Cardiovasc. Ther. 2011;29(3):190–198. DOI: 10.1111/j.1755-5922.2010.00155.x

2. Liang S., Aiqun M., Jiwu L., Ping Z. TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients. Immunol. Res. 2016;64(2):424–30. DOI: 10.1007/s12026-015-8685-6

3. Yılmaz S., Sen F., Ünal S., Yayla C., Özeke Ö., Aras D., Topaloglu S., Aydogdu S. Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis. Scand. Cardiovasc. J. 2015; 49(1):39–44. DOI: 10.3109/14017431.2014.989537

4. Niccoli G., Dato I., Imaeva A.E., Antonazzo Panico R., Roberto M., Burzotta F., Aurigemma C., Trani C., Gramegna M., Leone A.M., Porto I., Crea F. Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study. Eur. Heart J. Cardiovasc. Imaging. 2014;15(8):917–25. DOI: 10.1093/ehjci/jeu035

5. Wang Z., Liu C., Fang H. Blood cell parameters and predicting coronary in-stent restenosis. Angiology. 2019;70(8):711–718. DOI: 10.1177/0003319719830495

6. Zaher N., Sattar Y., Mahmood S., Vacek T., Alraies M.C. COVID-19 infection complicated by a complete occlusion of the left circumflex artery with acute restenosis after drug-eluting stent placement. Cureus. 2020;12(9):e10708. DOI: 10.7759/cureus.10708

7. Dotsenko O., Chaturvedi N., Thom S.A., Wright A.R., Mayet J., Shore A., Schalkwijk C., Hughes A.D. Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men. J. Thromb. Haemost. 2007;5(10):2036–2042. DOI: 10.1111/j.1538-7836.2007.02711.x

8. Sarkar S., Kannan S., Khanna P., Singh A.K. Role of plateletto-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis. J. Med. Virol. 2022;94(1):211–221. DOI: 10.1002/jmv.27297

9. Falk E., Nakano M., Bentzon J.F., Finn A.V., Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur. Heart J. 2013;34(10):719–28. DOI: 10.1093/eurheartj/ehs411

10. Lindemann S., Krämer B., Seizer P., Gawaz M. Platelets, inflammation and atherosclerosis. J. Thromb. Haemost. 2007; 5 Suppl 1:203–211. DOI: 10.1111/j.1538-7836.2007.02517.x

11. Horne B.D., Anderson J.L., John J.M., Weaver A., Bair T.L., Jensen K.R., Renlund D.G, Muhlestein J.B. Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk? J. Am. Coll. Cardiol. 2005;45(10):1638–1643. DOI: 10.1016/j.jacc.2005.02.054

12. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31–47. DOI: 10.1016/S0008-6363(01)00434-5

13. Major A.S., Fazio S., Linton M.F. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 2002;22:1892–1898. DOI: 10.1161/01.atv.0000039169.47943.ee

14. Widmer A., Linka A.Z., Attenhofer Jost C.H., Buergi B., Brunner-La Rocca H.P., Salomon F., Seifert B., Jenni R. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99(1):25–31. DOI: 10.1159/000068448

15. Li X.T., Fang H., Li D., Xu FQ., Yang B., Zhang R., An Y. Association of platelet to lymphocyte ratio with in-hospital major adverse cardiovascular events and the severity of coronary artery disease assessed by the Gensini score in patients with acute myocardial infarction. Chin. Med. J. 2020;133:415–423. DOI: 10.1097/CM9.0000000000000650

16. Azab B., Shah N., Akerman M., McGinn J.T.Jr. Value of platelet/ lymphocyte ratio as a predictor of all-cause mortality after non-STelevation myocardial infarction. J. Thromb. Thrombolysis. 2012;34:326–334. DOI: 10.1007/s11239-012-0718-6

17. Sun X.P., Li J., Zhu W.W., Li D.B., Chen H., Li H.W., Chen W.M., Hua Q. Impact of platelet-to-lymphocyte ratio on clinical outcomes in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68(4):346–353. DOI: 10.1177/0003319716657258

18. Maimaiti A., Li Y., Wang Y.T., Yang X., Li X.M., Yang Y.N., Ma Y.T. Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study. BMJ Open. 2019;9(9):e025628. DOI: 10.1136/bmjopen-2018-025628

19. Lee Y.S.G., Baradi A., Peverelle M., Sultani R., Adams H., Garlick J., Wilson A.M. Usefulness of platelet-to-lymphocyte ratio to predict long-term all-cause mortality in patients at high risk of coronary artery disease who underwent coronary angiography. Am. J. Cardiol. 2018;121(9):1021–1026. DOI: 10.1016/j.amjcard.2018.01.018

20. Li H., Zhou Y., Ma Y., Han S., Zhou L. The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis. Kardiol. Pol. 2017;75:666–673. DOI: 10.5603/KP.a2017.0068

21. Li W., Liu Q., Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Sci. Rep. 2017;7:40426. DOI: 10.1038/srep40426.

22. Wang H., Li L., Ma Y. Platelet‐to‐lymphocyte ratio a potential prognosticator in acute myocardial infarction: a prospective longitudinal study. Clin. Cardiol. 2023;46:632‐638. DOI: 10.1002/clc.24002

23. Alahwal H.M., Alsharif M.H., Alsharif M.H., Almohammadi AT., Al-Marzouki AF., Barefah AS., Bahashwan SM., Radhwi OO., Damanhouri GA. COVID-19-induced immune thrombocytopenia management approach: A case report and literature review. Clin. Case Rep. 2024;12(6):e9070. DOI: 10.1002/ccr3.9070

24. Chen Y., Liu J., Shao S., Song Z., Ma Y., Tuo Y., Fang L., Xu Y., Xu B., Gu W., Cao X., Chen J., Yang Y., Wang P., Zhang J., Xu Y., Yu D., Hou P., Meng K., Li Z., Liu G., Qu X., Ji L., Yang R., Zhang L. Characteristics and outcomes of COVID-19 in Chinese immune thrombocytopenia patients: A prospective cohort study. Br. J. Haematol. 2024;204(4):1207–1218. DOI: 10.1111/bjh.19198.

25. Tane M., Kosako H., Sonoki T., Hosoi H. TAFRO Syndrome and COVID-19. Biomedicines. 2024;12(6):1287. DOI: 10.3390/biomedicines12061287

26. Shamis D.V. Risk factors for coronary artery restenosis during emergency or elective stenting. Bulletin of Modern Clinical Medicine. 2019;12(4):116–123. (In Russian). DOI: 10.20969/VSKM.2019.12(4).116-123